securities class action

Vistagen's failed drug trial caused 81% stock drop. Securities lawsuit filed for investors who bought shares April 2024-December 2025. Lead plaintiff deadline: March 16, 2026.

Kyndryl faces securities fraud investigation after disclosing audit review of cash management and internal controls. Stock fell 50%; class action deadline set for April 13.

Bath and Body Works faces securities lawsuit alleging false statements about business strategy. Stock dropped 24.8% after missing Q3 guidance with declining revenue and net income.

Smart Digital shareholders have until March 16, 2026, to join a federal securities lawsuit alleging executives made false statements causing an 86.4% stock decline and trading suspension.

Inovio Pharmaceuticals faces securities lawsuit over false statements about manufacturing and regulatory prospects. FDA rejected accelerated approval for lead drug candidate, causing 24% stock drop.

Richtech Robotics faces securities lawsuit over false Microsoft partnership claims. Stock fell 20.87% after critical report questioned the deal's legitimacy.

AGL faces securities fraud allegations over false 2025 guidance. Stock plunged 51.5% after guidance suspension; investors have until March 2026 deadline to join class action.

BellRing Brands faces securities lawsuit over allegedly false statements about sales growth. Investors have until March 23 to join the class action suit.

Varonis Systems faces securities lawsuit alleging false ARR projections. Investors who bought shares Feb-Oct 2025 can join; March 9, 2026 deadline to apply.

BellRing Brands faces securities lawsuit alleging it misrepresented sales growth, claiming inventory stockpiling drove numbers rather than organic demand. Lead plaintiff deadline: March 23, 2026.

LuxUrban Hotels settles securities lawsuit through D&O insurance with no defendant contribution or admission of liability. Plaintiffs faced significant legal obstacles during litigation.

LuxUrban Hotels settled a securities lawsuit without admitting liability. The insurance-funded agreement resolved fraud allegations regarding lease arrangements and operational projections.

Investors in Mereo BioPharma face April deadline in class action lawsuit alleging executives misrepresented clinical trial results for setrusumab drug, causing stock losses.

Kyndryl stock plunges 55% after disclosing internal control weaknesses, management departures, and SEC inquiry, triggering securities lawsuit over prior misrepresentations.

SLM Corporation faces securities lawsuit over allegedly false statements about loan delinquencies. Investors have until February 17, 2026 to file lead plaintiff claims.

SDM investors face March 16, 2026 deadline to join securities fraud class action alleging material misrepresentations and market manipulation scheme.

Rosen Law Firm investigates KDDI for delayed earnings disclosure and potential securities violations. Stock fell 11.4% following announcement of internal investigation.